MSD's 2026 sales forecast falls short amid patent losses despite strong Q4 [Yahoo! Finance]
Revolution Medicines (NASDAQ:RVMD) had its price target raised by analysts at JPMorgan Chase & Co. from $92.00 to $122.00. They now have an "overweight" rating on the stock.
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
Merck Ends Revolution Medicines Talks As Oncology Plans And Valuation Weighed [Yahoo! Finance]
Revolution Medicines (NASDAQ:RVMD) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..